(2S,3S)-3-(2-ethoxy-5-trifluoromethoxybenzyl)-amino-2-phenyl-piperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (2S,3S)-3-(2-ethoxy-5-trifluoromethoxybenzyl)-amino-2-phenyl-piperidine
• 英文别名: (2S,3S)-3-(2-ethoxy-5-trifluoromethoxybenzyl) amino-2-phenyl-piperidine；(2S,3S)-3-(2-ethoxy-5-trifluoromethoxybenzyl)amino-2-phenyl-piperidine；(2S,3S)-3-(2-ethoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine；(2-Ethoxy-5-trifluoromethoxy-benzyl)-((2S,3S)-2-phenyl-piperidin-3-yl)-amine；(2S,3S)-N-[[2-ethoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine
• 化学式: C₂₁H₂₅F₃N₂O₂
• 分子量: 394.437
• InChiKey: ZPQUTMAPZMKLCT-ICSRJNTNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  42.5
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (2S,3S)-N-[(2-甲氧基苯基)甲基]-2-苯基-3-哌啶胺 在 platinum(IV) oxide 氢气 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 (2S,3S)-3-(2-ethoxy-5-trifluoromethoxybenzyl)-amino-2-phenyl-piperidine
  参考文献：
  名称：

  Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist

  摘要：

  The synthesis and SAR of benzylamine side chain analogs of the NK-1 receptor antagonist CP-99,994 are described. The 5-trifluoromethoxy analog, CP-122,721, shows superior in vivo blockade of NK-1 receptor mediated responses. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00012-2

文献信息

• Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
  申请人：——

  公开号：US20020035147A1

  公开（公告）日：2002-03-21

  The present invention relates to methods of treating various CNS and other disorders by adminstering fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, by administering compounds of the formula 1 wherein Q, X 1 , X 2 and X 3 are as defined below, and their pharmaceutically acceptable salts.

  本发明涉及通过给予含氮杂环化合物的氟烷氧基苄胺衍生物来治疗各种中枢神经系统和其他疾病的方法，具体地，通过给予以下公式中的化合物来治疗： 1 其中Q、X 1 、X 2 和X 3 如下所定义，并且它们的药用盐。
• [EN] QUINOLINE DERIVATIVES<br/>[FR] DERIVES QUINOLINIQUES
  申请人：PFIZER PROD INC

  公开号：WO2004043929A1

  公开（公告）日：2004-05-27

  The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, and n are as defined, and to pharmaceutically acceptable salts of said compounds. Compounds of Formula I have activity in agonizing 5HT7 receptors and are useful in treating, for example, disorders that can be treated by modulating circadian rhythms.

  本发明涉及式I的化合物，其中R1、R2、R3、R4和n如定义所述，并且涉及所述化合物的药用可接受的盐。式I的化合物在激活5HT7受体方面具有活性，并且可用于治疗例如可以通过调节昼夜节律来治疗的疾病。
• 5HT7 Antagonists and inverse agonists
  申请人：Pfizer Inc.

  公开号：US20040229874A1

  公开（公告）日：2004-11-18

  The present invention relates to compounds of formula I, 1 and the pharmaceutically acceptable salts thereof. These compounds are useful as psychotherapeutic agents.

  本发明涉及公式I的化合物及其药用盐。这些化合物可用作心理治疗药物。
• Pharmaceutical composition and method of modulating cholinergic function in a mammal
  申请人：Pfizer Inc.

  公开号：US20030008892A1

  公开（公告）日：2003-01-09

  A pharmaceutical composition and method of modulating cholinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of a diorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compositions is also disclosed.

  一种药物组合物及其在哺乳动物中调节胆碱能功能的方法，包括给予NRPA化合物或其药学上可接受的盐；以及抗恶心/抗呕吐剂或其药学上可接受的盐；和药学上可接受的载体。NRPA化合物和抗恶心/抗呕吐剂的含量使组合物能够有效调节胆碱能功能或用于治疗炎症性肠病（包括但不限于溃疡性结肠炎、化脓性坏疽和克罗恩病）、肠易激综合症、痉挛性肌张力障碍、慢性疼痛、急性疼痛、乳糜泻、袋炎、血管收缩、焦虑、惊恐障碍、抑郁症、躁郁症、自闭症、睡眠障碍、时差反应、肌萎缩侧索硬化症（ALS）、认知功能障碍、高血压、贪食症、厌食症、肥胖症、心脏心律失常、胃酸过多分泌、溃疡、嗜铬细胞瘤、进行性核上性麻痹、化学依赖和成瘾（例如对尼古丁（和/或烟草制品）、酒精、苯二氮卓、巴比妥类药物、阿片类药物或可卡因的依赖或成瘾）、头痛、偏头痛、中风、创伤性脑损伤（TBI）、强迫症、精神病、亨廷顿舞蹈症、迟发性运动障碍、过动症、阿尔茨海默病的老年性痴呆、帕金森病（PD）、注意力缺陷多动障碍（ADHD）和抽动症。还公开了使用这些组合物的方法。
• New pharmaceutical combinations for NOS inhibitors
  申请人：Pfizer Inc

  公开号：US20040229911A1

  公开（公告）日：2004-11-18

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂活性的化合物的新药物用途。具体地，涉及使用NOS抑制剂，特别是选择性神经元NOS（nNOS）抑制剂，单独或与另一种活性剂联合使用，特别是SSRI或NK-1受体拮抗剂，用于治疗可以通过改变昼夜节律来达到或促进治疗的疾病或病况。这些疾病和病况的例子包括失明、肥胖症、季节性情感障碍、双相情感障碍、时差反应、昼夜节律睡眠障碍、睡眠剥夺、睡眠障碍、REM睡眠障碍、嗜睡症、睡眠-觉醒周期障碍、嗜睡症和与轮班工作或不规则工作时间表相关的睡眠障碍、夜尿症和不宁腿综合症。